Search
Displaying 131–140 of 790 for “retinitis clinical trial”
-
Atsena to Launch Part B of Phase 1/2 Clinical Trial for XLRS Gene Therapy
Research NewsThe Foundation is a founding investor in Atsena.
-
Beacon's emerging XLRP gene therapy improves low-light vision in phase 3 trial
Research NewsBeacon plans to begin a rolling FDA submission for laru-zova later this year
-
FFB-CRI Leads Effort to Identify Outcome Measures for Therapies in Clinical Trials
Research NewsImproved outcome measures will make clinical trials for degenerative retinal diseases — including age-related macular degeneration (AMD), the world’s leading cause of blindness in seniors, and inherited retinal conditions such as RP and Stargardt disease — less expensive to conduct and able to deliver more precise results.
-
Stem-Cell Therapy for Retinitis Pigmentosa Safe Thus Far in Early Human Study
Research NewsThe trial is one of the first-ever for a stem-cell-derived therapy for RP.
-
Vision Testing and Retinal Imaging in Clinical Trials: What Patients Can Expect
Research NewsBecause measuring changes is not always easy, people in clinical trials often undergo a number of different tests over one or several years. It can be challenging for the patient, but is necessary to determine if a treatment is working.
-
Best Disease Gene Therapy Advances Toward Clinical Trial
Research NewsUsing gene therapy, FFB-funded researchers at the University of Pennsylvania School of Veterinary Medicine (Penn Vet) and Perelman School of Medicine have reversed the disease process in a canine model of Best disease, an inherited form of macular degeneration that can lead to severe vision loss in humans
-
New Imaging Technique May Be Game-Changer for RP Clinical Trials
Research NewsKnown as EZ Width, it holds potential for reducing the time, cost and number of patients needed to determine if a therapy is working in a clinical trial.
-
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
Research NewsThe MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
-
Disease
Often diagnosed in childhood or adolescence, retinitis pigmentosa (RP) is an inherited retinal disease causing progressive loss of night and peripheral vision. The condition often leads to legal and sometimes complete blindness.
.png)
